News|Articles|February 3, 2026 (Updated: February 16, 2026)
Turning Abandonment Scenarios into Patient Starts
Author(s)CoverMyMeds
Discover three strategies for overcoming high costs, prior authorization delays and rejected claims.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
Novo Nordisk Announces Significant Price Drops for Popular GLP-1 Medications
2
Merck’s Oncology Spin-Out: Organizational Design as Patent Cliff Strategy
3
Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-XTEN
4
Pharma Manufacturing Roundup: AbbVie Invests $380 Million to Expand API Manufacturing, Bora Pharmaceuticals and GSK Enters Five Year Manufacturing Agreement
5